Literature DB >> 24008295

The oncogenic role of hepatitis C virus.

Kazuhiko Koike1.   

Abstract

Persistent infection with hepatitis C virus (HCV) is a major risk toward development of hepatocellular carcinoma (HCC). However, it remains controversial in the pathogenesis of HCC associated with HCV whether the virus plays a direct or an indirect role. The observation that chronic hepatitis C patients with sustained high levels of serum alanine aminotransferase are prone to develop HCC suggests the significance of inflammation in hepatocarcinogenesis in hepatitis C. However, the rare development of HCC in patients with autoimmune hepatitis, which is accompanied by robust inflammation, even after the progress into cirrhosis, implies a possibility of the direct role of HCV in HCC development. What is the role of HCV, a simple plus-stranded RNA virus, whose genome is never integrated into the host genome, in hepatocarcinogenesis? The studies using transgenic mouse and cultured cell models, in which the HCV proteins are expressed, indicate the direct pathogenicity of HCV, including oncogenic activities. In particular, the core protein of HCV induces overproduction of oxidative stress by impairing the mitochondrial electron transfer system, through insulting the function of molecular chaperon, prohibitin. HCV also modulates the intracellular signaling pathways including mitogen-activated protein kinase, leading to the acquisition of growth advantage by hepatocytes. In addition, HCV induces disorders in lipid and glucose metabolisms, thereby accelerating the progression of liver fibrosis and HCC development. These results would provide a clue for further understanding of the role of HCV in pathogenesis of persistent HCV infection including hepatocarcinogenesis.

Entities:  

Mesh:

Year:  2014        PMID: 24008295     DOI: 10.1007/978-3-642-38965-8_6

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  6 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

2.  A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Authors:  Timothy R Morgan; Kathryn Osann; Teodoro Bottiglieri; Neville Pimstone; John C Hoefs; Ke-Qin Hu; Tarek Hassanein; Thomas D Boyer; Lorene Kong; Wen-Pin Chen; Ellen Richmond; Rachel Gonzalez; Luz M Rodriguez; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-30

Review 3.  Assessing cardiovascular risk in hepatitis C: An unmet need.

Authors:  Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-09-08

4.  Hepatitis C virus NS5A protein blocks epidermal growth factor receptor degradation via a proline motif- dependent interaction.

Authors:  Zsofia Igloi; Arunas Kazlauskas; Kalle Saksela; Andrew Macdonald; Jamel Mankouri; Mark Harris
Journal:  J Gen Virol       Date:  2015-04-13       Impact factor: 3.891

5.  A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets.

Authors:  N A Wijetunga; M Pascual; J Tozour; F Delahaye; M Alani; M Adeyeye; A W Wolkoff; A Verma; J M Greally
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

Review 6.  The Double-Edged Sword Role of Viruses in Gastric Cancer.

Authors:  Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Rafał Hrynkiewicz; Mikołaj Wołącewicz; Rafał Becht; Jacek Roliński
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.